Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial (Q84566153)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 July 2011

Language	Label	Description	Also known as
English	Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial	scientific article published on 20 July 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Claus G Roehrborn

1

object named as

Claus G Roehrborn

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

J Curtis Nickel

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Gerald L Andriole

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

R Paul Gagnier

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Libby Black

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Timothy H Wilson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Roger S Rittmaster

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

20 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

78

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

641-646

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

The progression of benign prostatic hyperplasia: examining the evidence and determining the risk

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Benign prostatic hyperplasia: a progressive disease of aging men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The long-term outcome of medical therapy for BPH.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Effect of dutasteride on the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The natural history of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.03.063

7 January 2021

Identifiers

10.1016/J.UROLOGY.2011.03.063

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21764428%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84566153&oldid=1978619437"